Marinus pharmaceuticals inc (MRNS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13
Expenses:
Research and development

49,098

42,966

38,541

36,117

33,339

28,394

23,651

17,145

12,730

12,376

13,445

15,643

20,084

22,005

23,653

22,285

18,942

18,916

15,022

13,119

12,009

8,690

7,531

7,289

0

0

0

General and administrative

11,639

11,456

10,683

10,429

10,265

8,785

8,191

7,689

7,042

6,667

6,592

6,550

6,445

6,237

6,155

6,004

5,673

5,516

5,468

4,958

4,161

3,230

2,155

1,601

0

0

0

Loss from operations

-60,737

-54,422

-49,224

-46,546

-43,604

-37,179

-31,842

-24,834

-19,772

-19,043

-20,037

-22,193

-26,529

-28,242

-29,808

-28,289

-24,615

-24,432

-20,490

-18,077

-16,170

-11,920

-9,686

-8,890

0

0

0

Interest income

480

354

441

459

434

454

500

434

400

324

152

143

146

128

0

0

0

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,192

-1,282

0

0

0

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

47

36

22

12

15

15

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

159

257

372

424

464

487

490

483

475

383

291

0

-

0

0

-

-

0

Other expense

-53

-53

0

0

0

-

-

-8

-12

-20

-32

-46

-58

-65

0

0

0

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

-

-

Net loss

-60,332

-54,115

-48,819

-46,129

-43,210

-36,726

-31,351

-24,411

-19,459

-18,898

-20,174

-22,468

-26,865

-28,643

-30,236

-28,735

-25,059

-24,850

-20,851

-17,556

-15,605

-10,833

-8,448

-8,462

0

0

0

Deemed divideds on convertible preferred stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cumulative preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,545

3,574

4,142

0

0

0

Net loss applicable to common shareholders

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,378

-12,023

-12,605

0

0

0

Per share information:
Net loss per share of common stock—basic and diluted

-0.32

-0.25

-0.26

-0.24

-0.24

-0.24

-0.27

-0.24

-0.15

-0.18

-0.15

-0.21

-0.26

-0.31

-0.33

-0.46

-0.37

-0.45

-0.35

-0.37

-0.50

13.12

-0.22

-7.98

-7.09

-4.58

-5.66

Basic and diluted weighted average shares outstanding

86,661

60,520

52,543

52,522

52,465

42,405

40,407

40,395

40,373

22,930

28,666

21,985

20,580

19,509

19,509

19,509

19,464

19,097

12,289

14,223

14,068

14,140

9,449

554

466

492

463

Net loss

-60,332

-54,115

-48,819

-46,129

-43,210

-36,726

-31,351

-24,411

-19,459

-18,898

-20,624

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive income (loss):
Unrealized gain on available-for-sale securities

0

-

0

-

107

94

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total comprehensive loss

-60,284

-54,121

-48,797

-46,060

-43,103

-36,632

0

0

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-